BiotechTube
RealSeq Biosciences

RealSeq Biosciences

San Diego, United States· Est.
realseq.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $300K

Overview

RealSeq Biosciences, founded in 2018 and based in San Diego, is pioneering the field of RNA fragmentomics to discover new biomarkers for advanced diagnostics. Its core technology, the RiboMarker® platform, combines a novel, low-bias library preparation method with NGS and AI-powered bioinformatics to analyze the >90% of cell-free RNA that current techniques cannot detect. The company is leveraging this platform to develop diagnostics, starting with a program for Valley Fever, while also generating revenue through the sale of sequencing kits and services to the research community. RealSeq is a privately held, NIH-funded company actively seeking research and industry collaborations.

OncologyInfectious Disease

Technology Platform

RiboMarker® platform for RNA fragmentomics: a proprietary, low-bias library preparation method (using single-adapter circularization) combined with NGS and AI bioinformatics to discover novel RNA biomarkers from the >90% of cfRNA missed by standard methods.

Funding History

1
Total raised:$300K
Grant$300K

Opportunities

The vast, untapped RNA fragmentome represents a major opportunity for discovering novel biomarkers with high clinical utility, particularly for dynamic monitoring of disease progression.
The growing liquid biopsy market demands complementary techniques to DNA analysis, creating a clear entry point for RNA fragmentomics.
Applications extend beyond human diagnostics into agricultural and environmental testing, broadening the potential market.

Risk Factors

The company must clinically validate that its novel RNA biomarkers translate into improved diagnostic outcomes, a long and costly process.
As a small, private player, it faces significant financing risk and intense competition from larger, well-established diagnostics and sequencing companies.
Technological obsolescence and the challenge of securing pivotal industry partnerships are ongoing threats.

Competitive Landscape

RealSeq competes in the crowded liquid biopsy and sequencing space, dominated by companies focusing on ctDNA (e.g., Guardant Health, GRAIL). Its differentiation lies in its exclusive focus on the underrepresented RNA fragmentome. It faces competition from other RNA-focused diagnostic companies and large NGS platform providers (Illumina, PacBio) who may develop similar capabilities. Its success hinges on proving its technology accesses uniquely informative biomarkers.

More companies in Diagnostics & Precision Medicine →More companies in United States →